ArticleApplied microbiology and biotechnology2026
Polycationic nanopeptide-fused endolysins for the control of Mannheimia haemolytica.
Article in Applied microbiology and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Bovine respiratory disease (BRD) remains a major economic and animal health concern in cattle production, exacerbated by rising antimicrobial resistance and limited vaccine efficacy. Endolysins, phage-derived peptidoglycan hydrolases, have emerged as promising alternatives to antibiotics, but their activity against gram-negative bacteria is hindered by the outer membrane (OM) barrier. In this study, we identified five distinct prophage-derived endolysins from Mannheimia haemolytica and successfully expressed two (185 and 587AP2) along with their engineered polycationic nanopeptide (PCNP) fusions (PCNP-185 and PCNP-587AP2). All four recombinant proteins demonstrated muralytic activity, with original endolysins exhibiting higher enzymatic efficiency. However, PCNP-fused variants showed superior antibacterial effects as compared to those without. Especially, PCNP-185 achieved the most consistent multi-log
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.